- Home
- PRQR vs ALEC Comparison
PRQR vs ALEC Comparison
Compare PRQR & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRQR | ALEC |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.5M | 194.3M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PRQR | ALEC |
|---|---|---|
| Price | $1.55 | $1.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $7.25 | $4.83 |
| AVG Volume (30 Days) | ★ 1.0M | 875.1K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | $13.92 | $29.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.33 | $1.09 |
| 52 Week High | $3.10 | $3.40 |
Technical Indicators
Market Signals| Indicator | PRQR | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 52.52 |
| Support Level | $1.39 | $1.14 |
| Resistance Level | $1.70 | $2.64 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 30.95 | 78.69 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.